Belvedere Trading
IRLA

Belvedere Trading’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Belvedere Trading’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-65
Closed -$1.32K – 1170
2026
Q1 		$1.32K Buy
+65
New +$13K ﹤0.01% 715

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Belvedere Trading's IRLA Position: Q2 2026 in Review

Belvedere Trading sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026, closing a stake of 65 shares — an estimated $1.32K sold.

Belvedere Trading first reported a position in IRLA in Q1 2026 and held it in 1 quarter. The position peaked at $1.32K in Q1 2026. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • Belvedere Trading reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
  • Belvedere Trading sold 65 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $1.32K.
  • Belvedere Trading first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2026 and held it in 1 quarter.
  • Belvedere Trading's IRulya Therapeutics Inc. Common Stock position peaked at $1.32K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Belvedere Trading's 13F filing for Q2 2026, filed 31 Jul 2026.